z-logo
Premium
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy
Author(s) -
Arnst Kinsie E,
Banerjee Souvik,
Chen Hao,
Deng Shanshan,
Hwang DongJin,
Li Wei,
Miller Duane D
Publication year - 2019
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21568
Subject(s) - mitosis , microtubule , drug , biology , tubulin , drug development , cancer , pharmacology , cancer research , computational biology , microbiology and biotechnology , genetics
Microtubule (MT)‐targeting agents are highly successful drugs as chemotherapeutic agents, and this is attributed to their ability to target MT dynamics and interfere with critical cellular functions, including, mitosis, cell signaling, intracellular trafficking, and angiogenesis. Because MT dynamics vary in the different stages of the cell cycle, these drugs tend to be the most effective against mitotic cells. While this class of drug has proven to be effective against many cancer types, significant hurdles still exist and include overcoming aspects such as dose limited toxicities and the development of resistance. Newer generations of developed drugs attack these problems and alternative approaches such as the development of dual tubulin and kinase inhibitors are being investigated. This approach offers the potential to show increased efficacy and lower toxicities. This review covers different categories of MT‐targeting agents, recent advances in dual inhibitors, and current challenges for this drug target.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here